PHARMACODYNAMIC RELATIONSHIP BETWEEN PCSK9, ALIROCUMAB, AND LDL-C LOWERING IN FOUR PHASE 3 ODYSSEY TRIALS WITH/WITHOUT STATIN BACKGROUND

被引：1

作者：

Robinson, J. G. ^{[1
,2
]}

Farnier, M. ^{[3
]}

Kastelein, J. J. ^{[4
]}

Roth, E. M. ^{[5
]}

Taskinen, M. R. ^{[6
,7
]}

Colhoun, H. M. ^{[8
]}

Brunet, A. ^{[9
]}

DiCioccio, A. T. ^{[10
]}

Lecorps, G. ^{[11
]}

Pordy, R. ^{[12
]}

Baccara-Dinet, M. T. ^{[13
]}

Cannon, C. P. ^{[14
]}

机构：

[1] Univ Iowa, Dept Epidemiol, Iowa City, IA USA

[2] Univ Iowa, Dept Med, Iowa City, IA 52242 USA

[3] Lipid Clin, Point Med, Dijon, France

[4] Acad Med Ctr, Dept Vasc Med, Amsterdam, Netherlands

[5] Sterling Res Grp NA, Cincinnati, OH USA

[6] Univ Helsinki, Heart & Lung Ctr, Helsinki Univ Hosp, Helsinki, Finland

[7] Res Programs Unit Diabet & Obes, Helsinki, Finland

[8] Univ Dundee, Populat Hlth Sci, Dundee, Scotland

[9] Sanofi, R&D, Paris, France

[10] Regeneron Pharmaceut Inc, Pharmacometr, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

[11] Sanofi, R&D Biostat, Paris, France

[12] Regeneron Pharmaceut Inc, Cardiovasc & Metab Therapeut, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

[13] Sanofi, Clin Dev, Montpellier, France

[14] Harvard Clin Res Inst NA, Boston, MA USA

来源：

ATHEROSCLEROSIS | 2016年 / 252卷

关键词：

D O I：

10.1016/j.atherosclerosis.2016.07.219

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

EAS16-0634

引用

页码：E231 / E231

页数：1

共 50 条

[1] Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial
Roth, Eli M.
Kastelein, John Jp
Cannon, Christopher P.
Farnier, Michel
McKenney, James M.
DiCioccio, A. Thomas
Brunet, Aurelie
Manvelian, Garen
Sasiela, William J.
Baccara-Dinet, Marie T.
Zhao, Jian
Robinson, Jennifer G.
JOURNAL OF CLINICAL LIPIDOLOGY, 2020, 14 (05) : 707 - 719
[2] Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses
Robinson, Jennifer G.
Farnier, Michel
Kastelein, John J. P.
Roth, Eli M.
Taskinen, Marja-Riitta
Colhoun, Helen M.
Brunet, Aurelie
DiCioccio, A. Thomas
Lecorps, Guillaume
Pordy, Robert
Baccara-Dinet, Marie T.
Cannon, Christopher P.
JOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (06) : 979 - 988
[3] Lowering LDL-C with alirocumab, an investigational PCSK9 inhibitor
Edelberg, Jay
CLINICAL LIPIDOLOGY, 2014, 9 (06) : 603 - 606
[4] RELATIONSHIP BETWEEN ALIROCUMAB, PCSK9 AND LDL-C LEVELS: RESULTS FROM THE ODYSSEY MONO PHASE 3 TRIAL OF ALIROCUMAB 75 MG EVERY 2 WEEKS
Farnier, M.
Kastelein, J. J. P.
Roth, E.
Taskinen, M. R.
Ginsberg, H. N.
Colhoun, H. M.
Robinson, J. G.
Merlet, L.
Brunet, A.
Pordy, R.
Baccara-Dinet, M. T.
ATHEROSCLEROSIS, 2014, 235 (02) : E34 - E35
[5] Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide
Viney, Nicholas J.
Yeang, Calvin
Yang, Xiaohong
Xia, Shuting
Witztum, Joseph L.
Tsimikas, Sotirios
JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (03) : 702 - 710
[6] Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering
Rodriguez, Fatima
Harrington, Robert A.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (19): : 1967 - 1968
[7] PCSK9抑制剂Alirocumab降低LDL-C的研究新进展
范致星
杨超君
杨简
海南医学, 2015, (15) : 2262 - 2264
[8] Relationship Between Baseline PCSK9 and LDL-C Reduction in Response to the Investigational RNAi Therapeutic Inclisiran
Stoekenbroek, Robert M.
Kallend, David
Wijngaard, Peter L.
Wright, R. Scott
Landmesser, Ulf
Leiter, Lawrence A.
Kastelein, John J.
Ray, Kauik K.
CIRCULATION, 2018, 138
[9] Is sEHi lowering LDL-C by reducing expression of PCSK9 through SREBP2 pathway?
Liu, Qiong
Guo, Yuan
Gui, Ya-jun
Liao, Cai-xiu
Xu, Dan-yan
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 207 : 361 - 362
[10] NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY
Strat, A. L.
Ghiciuc, Cristina Mihaela
Lupusoru, Catalina Elena
Mitu, F.
MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2016, 120 (02): : 228 - 232

← 1 2 3 4 5 →